-
AC008406.3, Cuproptosis, and Docetaxel Sensitivity
2026-08-18
This study identifies the lncRNA AC008406.3 as a negative regulator of cuproptosis and docetaxel response in breast cancer models. Its integrated transcriptomic and experimental design suggests that suppressing AC008406.3 may enhance docetaxel activity, although clinical validation and mechanistic refinement are still needed.
-
Methicillin Sodium Salt: MSSA Assay Workflow
2026-08-17
Build more interpretable MSSA susceptibility assays with Methicillin sodium salt as a mechanistically anchored benchmark. This guide connects concentration design, orthogonal target-validation logic, and troubleshooting for Staphylococcus aureus infection research while clearly separating MSSA activity from MRSA resistance.
-
Cefodizime: PBP Mechanism to Assay Design
2026-08-17
Cefodizime is a third-generation cephalosporin antibiotic whose PBP targeting, β-lactamase stability, pharmacokinetics, and immune-related effects create a nuanced research profile. This guide translates those properties into better antimicrobial assay design and interpretation.
-
TBST for Reliable Immunoassay Workflows
2026-08-16
Learn how TBST supports cleaner Western blots, immunofluorescence, immunohistochemistry, and immunocytochemistry through controlled blocking and washing. The workflow also shows how assay design can validate uPAR·uPA inhibitor activity without confusing improved image quality with biological efficacy.
-
Annexin V-Cy5/DAPI Apoptosis Kit Workflow
2026-08-15
Build a rapid, two-parameter cell-death workflow that separates viable, early apoptotic, late apoptotic, and necrotic populations. The assay also provides a practical phenotypic readout for mechanistic studies such as P2RX1-driven mitochondrial apoptosis and tyrosine kinase inhibitor response in Ph+ ALL.
-
Temafloxacin: Mechanism, MICs, and Research Use
2026-08-14
Temafloxacin is a fluoroquinolone broad-spectrum antibacterial agent that targets bacterial DNA gyrase and topoisomerase IV. Comparative in vitro data show low MIC values against several respiratory, sexually transmitted, Gram-positive, and intracellular bacterial targets, while assay conditions, solvent handling, and organism-specific susceptibility limit interpretation.
-
RESTRICT-seq Maps Epigenetic Dependencies in SCC
2026-08-14
The bioRxiv preprint introducing RESTRICT-seq presents a time-gated CRISPR screening strategy for resolving when epigenetic regulators influence squamous cell carcinoma resistance. The study identifies KAT6A and related acetyltransferase activity as candidate dependencies, providing a framework for connecting resistance phenotypes with experimentally testable chromatin mechanisms.
-
Cefodizime and the Next Generation of AMR Research
2026-08-13
Cefodizime offers translational researchers more than a conventional antibacterial readout: it is a mechanistically defined PBP-targeting probe that can connect bacterial killing, resistance ecology, host phagocytic function, and exposure design. This article presents a research strategy for using Cefodizime to interrogate antimicrobial activity against respiratory and urinary tract infections while respecting its spectrum boundaries and the realities of antimicrobial resistance.
-
Dovitinib (TKI-258): RTK Mechanism & Research Use
2026-08-13
Dovitinib, also called TKI-258 and CHIR-258, is a multitargeted receptor tyrosine kinase inhibitor used to study FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling. Its reported low-nanomolar activity supports research on apoptosis induction in cancer cells, while formulation and model limitations require careful experimental controls.
-
Aztreonam: Mechanism, Evidence, and Research Use
2026-08-12
Aztreonam is a monocyclic β-lactam antibiotic with activity directed mainly toward Gram-negative aerobic bacteria. Its documented research value spans bacterial cell wall studies, bone marrow progenitor cell inhibition, and effects on liver cytochrome P450 enzymes, while its product specifications support aqueous and DMSO-based assay preparation.
-
MK-0812 and the Gut–Liver Immune Axis in MASH
2026-08-12
A mechanism-first perspective on using MK-0812 to test whether CCR2-dependent monocyte recruitment links intestinal TM6SF2 deficiency, gut–liver signaling, and hepatic inflammation in MASH models.
-
RESTRICT-seq Maps KAT6A Dependency in SCC Resistance
2026-08-11
The bioRxiv preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy designed to resolve epigenetic dependencies that emerge during squamous cell carcinoma resistance. Its identification of KAT6A as a resistance-associated vulnerability connects chromatin regulation with cell-state control and provides a rationale for temporally resolved genetic and pharmacological validation.
-
Ciprofloxacin in Precision Nanotheranostic Workflows
2026-08-11
Ciprofloxacin supports both mechanism-driven antibacterial assays and emerging ultrasound-responsive nanotheranostic research. This guide connects DNA replication inhibition, antimicrobial resistance research, and the FA-PEG@ZIF8@CIP workflow while emphasizing formulation controls, quantitative readouts, and translational limitations.
-
Annexin V-Cy5/DAPI Apoptosis Kit Guide
2026-08-10
The Annexin V-Cy5/DAPI Apoptosis Kit provides rapid, dual-parameter apoptosis and necrosis differentiation through phosphatidylserine exposure and membrane-impermeant DNA staining. The K2255 workflow supports fluorescence microscopy and flow cytometry for cell apoptosis assay development, cytotoxicity testing, and programmed cell death detection.
-
Murine RNase Inhibitor for RNA-Safe Assays
2026-08-09
Murine RNase Inhibitor protects RNA in RT-PCR, cDNA synthesis, in vitro transcription, and modification-sensitive workflows where oxidation and residual nucleases threaten data quality. Its pancreatic-type RNase specificity and activity under low-DTT conditions make it especially useful for carefully controlled RNA integrity experiments.